Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision | ||
pharmaceutical_companies:novartis [2022/01/27 19:49] liam [Payments from Novartis] | pharmaceutical_companies:novartis [2022/02/21 20:00] (current) liam | ||
---|---|---|---|
Line 2: | Line 2: | ||
{{ : | {{ : | ||
+ | |||
+ | FIXME | ||
+ | |||
+ | ==== History ==== | ||
+ | |||
+ | Novartis was created in 1996 through a merger of [[Ciba-Geigy]] and [[Sandoz]]. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing [[chemicals]] and ultimately pharmaceuticals. | ||
+ | |||
+ | The history of Novartis traces the converging destinies of three companies; Geigy, a chemicals and dyes trading company founded in Basel, Switzerland in the middle of the 18th century; Ciba, which began producing dyes in 1859; and Sandoz, a chemical company founded in Basel in 1886. | ||
+ | |||
+ | On 1758, Johann Rudolph Geigy-Gemuseus (1733-1793) fiunded trading company J.R. Geigy in Basel, Switzerland to deal in " | ||
+ | |||
+ | In 1859 Alexander Clavel (1805-1873) takes up the production of [[fuchsine]] a synthetic dye, in his silk dying factory in Basel, Switzerland. | ||
+ | |||
+ | In 1886 the chemical company Kern & Sandoz is founded in Basel, Switzerland by Dr. Alfred Kern (1850-1893) and Edouard Sandoz (1853-1928). The first dyes produced are alizarin blue and auramine. | ||
+ | |||
+ | In 1900 Ciba produces its first pharmaceutical substance; Vioform and anticeptic and Salen, an antirheumatid agent. | ||
+ | |||
+ | ((https:// | ||
+ | |||
+ | **Novartis AG** is a multinational pharmaceutical company headquartered in Switzerland. | ||
+ | |||
+ | Made up of two business units – [[Novartis Pharmaceuticals]] which includes [[Novartis Gene Therapies]], | ||
+ | |||
+ | [[Sandoz]] is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines. | ||
+ | Advanced Accelerator Applications | ||
+ | |||
+ | [[Advanced Accelerator Applications]] is a Novartis company focused exclusively on radioligand therapy and precision imaging.((https:// | ||
+ | |||
+ | ===== Affiliations ===== | ||
+ | |||
+ | Novartis is a member organization of the [[:World Economic Forum]].((// | ||
===== Payments from Novartis ===== | ===== Payments from Novartis ===== | ||
Line 8: | Line 39: | ||
^ Name ^ Type ^ Amount | ^ Name ^ Type ^ Amount | ||
- | | [[:Menaka Pai]] | Speakers Bureau/ | + | | [[:Menaka Pai]] | Speakers Bureau/ |
+ | |||
+ | |||
+ | ==== ==== | ||
+ | About Novartis Commitment to Oncology Cell & Gene | ||
+ | Novartis has a mission to reimagine medicine by bringing curative cell & gene therapies to patients worldwide. Novartis has a deep CAR-T pipeline and ongoing investment in manufacturing and supply chain process improvements. With active research underway to broaden the impact of cell and gene therapy in oncology, Novartis is going deeper in hematological malignancies, | ||
+ | |||
+ | Novartis was the first pharmaceutical company to significantly invest in pioneering [[CAR-T]] research and initiate global CAR-T trials. Kymriah, the first approved CAR-T cell therapy, developed in collaboration with the [[Perelman School of Medicine]] at the [[University of Pennsylvania]], | ||
+ | |||
+ | Kymriah is currently approved for use in at least one indication in 30 countries and at more than 345 certified treatment centers, with the ambition for further expansion to help fulfill the ultimate goal of bringing CAR-T cell therapy to every patient in need. | ||
+ | |||
+ | Novartis has an expansive global CAR-T manufacturing footprint that includes both Novartis-owned and contract manufacturing sites. This comprehensive, | ||
+ | |||
+ | Important Safety information from the Kymriah SmPC | ||
+ | Kymriah (tisagenlecleucel) is an autologous, immunocellular cancer therapy which involves reprogramming a patient' | ||
+ | |||
+ | Kymriah is indicated for the treatment of pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse as well as for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. ((https:// | ||
+ | |||
+ | ==== Press Release Disclaimer ==== | ||
+ | Disclaimer | ||
+ | This press release contains forward-looking statements within the meaning of the United States [[Private Securities Litigation Reform Act of 1995]]. Forward-looking statements can generally be identified by words such as “potential, | ||
+ | |||
+ | **You should not place undue reliance on these statements.** Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, | ||
+ | |||
+ | There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, | ||
+ | |||
+ | Novartis is providing the information in this press release as of this date and **does not undertake any obligation to update any forward-looking statements** contained in this press release as a result of new information, |